Key result
Glycoprotein IIb/IIIa inhibitors reduced the 30-day rate of death or myocardial infarction to 10.8% compared to 11.8% for placebo in patients with non-ST elevation acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
Describes the role of the National Institute for Clinical Excellence (NICE) in evaluating therapies like glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hyde et al. (2003) conducted an editorial in non-ST elevation acute coronary syndromes (n=31,402). Glycoprotein IIb/IIIa inhibitors vs. Placebo was evaluated on 30-day rate of death or MI (OR 0.91, 95% CI 0.84-0.98). Glycoprotein IIb/IIIa inhibitors reduced the 30-day rate of death or myocardial infarction to 10.8% compared to 11.8% for placebo in patients with non-ST elevation acute coronary syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: